Reform of EU pharmaceutical legislationOverview of the proposed reform of EU pharmaceutical legislation: its objectives, key changes and expected impact on patients and industry.Critical medicines ActEU proposal to strengthen availability and supply of critical medicines, tackle shortages and boost resilience of essential medicine supply chains.Clinical trialsOverview of clinical trials in the EU: their purpose, how they are authorised and conducted, and the regulatory framework.BiotechnologyEU efforts to advance biotechnology, boost innovation and strengthen competitiveness in health and industry across the EU.Falsified medicinesInformation on risks from falsified medicines and EU measures to prevent and control fake products entering the supply chain.Good manufacturing practicesOverview of EU requirements for good manufacturing and distribution practices to ensure quality of medicines and active substances.EudralexThe EU body of pharmaceutical law and supporting guidelines that govern medicinal products and their regulatory framework.Legal frameworkPharmaceutical strategy for Europe (2020)Product typesMedicines for ChildrenOrphan medicinal productsAdvanced TherapiesHerbal Medicinal ProductsPersonalised medicineUnion RegisterDetails of medicinal products authorised in the EU, including product names, active substances and marketing authorisation information.Other topicsPharmaceutical committeeCall for EMA committees and board membersPharmacovigilancePharmaceuticals and the environmentInternational cooperation on pharmaceuticalsEU logo Latest updatesNews announcement22 April 2026Commission authorises first combined COVID-19 and influenza vaccine for people 50 years and older1 min readNews announcement19 March 2026Agenda - 103rd meeting of the Pharmaceutical Committee (27 March 2026)1 min readNews announcement5 March 2026Consultation of new guidance on the conduct of clinical trials during public health emergencies in the EU1 min readNews announcement20 February 2026Presentation and recording - EUHPP Live Webinar on Biosimilars policies and (best) practices - Evidence from the AUGMENT Biosimilar study (19 February 2026)1 min readSee all HighlightsClinical trialsCritical medicines ActBiotechnology Events24Feb2026Partner meetingsMeeting of the National Competent Authorities on Pricing and Reimbursement and Public Healthcare Payers (NCAPR)Belgium04Dec2025Partner meetingsBiosimilar medicines - Multistakeholder Event06-07Nov2025Partner meetingsMeeting of the National Competent Authorities on Pricing and Reimbursement and Public Healthcare Payers (NCAPR)Denmark17Sep2025Partner meetingsMeeting of the National Competent Authorities on Pricing and Reimbursement and Public Healthcare Payers (NCAPR)Belgium DocumentsEventsConsultationsPublicationsVideosEurobarometers
Reform of EU pharmaceutical legislationOverview of the proposed reform of EU pharmaceutical legislation: its objectives, key changes and expected impact on patients and industry.
Critical medicines ActEU proposal to strengthen availability and supply of critical medicines, tackle shortages and boost resilience of essential medicine supply chains.
Clinical trialsOverview of clinical trials in the EU: their purpose, how they are authorised and conducted, and the regulatory framework.
BiotechnologyEU efforts to advance biotechnology, boost innovation and strengthen competitiveness in health and industry across the EU.
Falsified medicinesInformation on risks from falsified medicines and EU measures to prevent and control fake products entering the supply chain.
Good manufacturing practicesOverview of EU requirements for good manufacturing and distribution practices to ensure quality of medicines and active substances.
EudralexThe EU body of pharmaceutical law and supporting guidelines that govern medicinal products and their regulatory framework.
Product typesMedicines for ChildrenOrphan medicinal productsAdvanced TherapiesHerbal Medicinal ProductsPersonalised medicine
Union RegisterDetails of medicinal products authorised in the EU, including product names, active substances and marketing authorisation information.
Other topicsPharmaceutical committeeCall for EMA committees and board membersPharmacovigilancePharmaceuticals and the environmentInternational cooperation on pharmaceuticalsEU logo
News announcement22 April 2026Commission authorises first combined COVID-19 and influenza vaccine for people 50 years and older1 min read
News announcement19 March 2026Agenda - 103rd meeting of the Pharmaceutical Committee (27 March 2026)1 min read
News announcement5 March 2026Consultation of new guidance on the conduct of clinical trials during public health emergencies in the EU1 min read
News announcement20 February 2026Presentation and recording - EUHPP Live Webinar on Biosimilars policies and (best) practices - Evidence from the AUGMENT Biosimilar study (19 February 2026)1 min read
24Feb2026Partner meetingsMeeting of the National Competent Authorities on Pricing and Reimbursement and Public Healthcare Payers (NCAPR)Belgium
06-07Nov2025Partner meetingsMeeting of the National Competent Authorities on Pricing and Reimbursement and Public Healthcare Payers (NCAPR)Denmark
17Sep2025Partner meetingsMeeting of the National Competent Authorities on Pricing and Reimbursement and Public Healthcare Payers (NCAPR)Belgium
